Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Anne J Kugler, Michael L Thiman

Abstract

Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from -0.78% to -1.64% over 52-104 weeks, and it consistently outperformed each of these agents. As an add-on therapy, dulaglutide provided additional A1c lowering of -1.4% to -1.44% over monotherapy with glimepiride or glargine at 24 and 28 weeks, respectively. Dulaglutide outperformed exenatide when added to a regimen of metformin with pioglitazone as well as glargine when added to a regimen of metformin with glimepiride. Dulaglutide was shown to be non-inferior to liraglutide when added to metformin. In all AWARD studies other than when compared to liraglutide, dulaglutide at full strength resulted in significantly more patients achieving their A1c goal. Recent class-wide meta-analyses indicate that the incidence of commonly experienced gastrointestinal (GI) side effects is dose dependent, and nausea and vomiting are less common in longer-acting agents such as dulaglutide, but diarrhea may be more common. Pooled data have shown no increased risk of serious side effects such as...Continue Reading

Citations

Dec 14, 2018·Cardiovascular Diabetology·Andrei C SpositoJosé Francisco Kerr Saraiva
Jul 28, 2019·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Spyridon N KarrasKalliopi Kotsa
Jun 27, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jee Hee YooWoo Je Lee
Jun 22, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Richard J MacIsaac
Sep 14, 2019·Endocrine Regulations·Eiji KutohAlexandra N Kuto
Jul 17, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraNitin Kapoor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Expert Review of Clinical Pharmacology
André J Scheen
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Angela M Thompson, Jennifer M Trujillo
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Allen B KingGiorgio Sesti
© 2022 Meta ULC. All rights reserved